scholarly journals Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group

2019 ◽  
Vol 66 (9) ◽  
Author(s):  
Uma Athale ◽  
Nobuko Hijiya ◽  
Briana C. Patterson ◽  
John Bergsagel ◽  
Jeffrey R. Andolina ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Children And Adolescents ◽  
Working Group ◽  
Myeloid Leukemia ◽  
Oncology Group ◽  
Leukemia In Children

scholarly journals Chronic myeloid leukemia in children and adolescents (A bout 2 cases)

2021 ◽  
Author(s):  
meryeme abddaoui ◽  
ahmed faleh ◽  
imane tlemçani ◽  
sara ben miloud ◽  
moncef amrani hassani
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Children And Adolescents ◽  
Myeloid Leukemia ◽  
Kinase Activity ◽  
Fusion Gene ◽  
Rare Entity ◽  
Tyrosine Kinase Activity ◽  
Leukemia In Children

Pediatric chronic myeloid leukemia is a rare entity (2-5% of childhood leukemias) classified as a myeloproliferative neoplasia characterized by the presence of the BCR-ABL fusion gene, the oncogenic translocation product (9; 22) responsible for the disease through its deregulated tyrosine kinase activity.

Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate

2012 ◽  
Vol 53 (12) ◽  
pp. 2430-2433 ◽  
Author(s):  
K. C. Lakshmaiah ◽  
Rohan Bhise ◽  
Samit Purohit ◽  
Linu J. Abraham ◽  
D. Lokanatha ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Children And Adolescents ◽  
Imatinib Mesylate ◽  
Myeloid Leukemia ◽  
Results Of Treatment ◽  
Leukemia In Children

scholarly journals How I treat chronic myeloid leukemia in children and adolescents

Blood ◽  
2019 ◽  
Vol 133 (22) ◽  
pp. 2374-2384 ◽  
Author(s):  
Nobuko Hijiya ◽  
Meinolf Suttorp
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Children And Adolescents ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Clinical Investigation ◽  
Limited Experience ◽  
Poor Treatment ◽  
Third Line ◽  
Treatment Free Remission ◽  
Leukemia In Children

AbstractEvidence-based recommendations have been established for treatment of chronic myeloid leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this leukemia in children and adolescents makes it challenging to develop similar recommendations in pediatrics. In addition to imatinib, which was approved for pediatric CML in 2003, the second-generation TKIs dasatinib and nilotinib were recently approved for use in children, expanding the therapeutic options and pushing allogeneic stem cell transplantation to a third-line treatment of most pediatric cases. Yet, without sufficient data on efficacy and safety specific to pediatric patients, the selection of a TKI continues to rely on clinical experience in adults. Here, we present 4 case scenarios highlighting common yet challenging issues encountered in the treatment of pediatric CML (suboptimal response, poor treatment adherence, growth retardation, and presentation in advanced phases). Limited experience with very young children, the transition of teenagers to adult medicine, and the goal of achieving treatment-free remission for this rare leukemia are additional significant obstacles that require further clinical investigation through international collaboration.

scholarly journals Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors

2021 ◽  
Vol 22 (15) ◽  
pp. 7806
Author(s):  
Maria Moschovi ◽  
Charikleia Kelaidi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Children And Adolescents ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Hematopoietic Cell Transplantation ◽  
Adult Life ◽  
Normal Growth ◽  
Molecular Response ◽  
Treatment Paradigm ◽  
Treatment Free Remission

Chronic myeloid leukemia (CML) is a rare disease in children and adolescents. The goal of therapy in children and adolescents is normal life expectancy, without compromising normal growth and development and potential for achievement of milestones in adult life. The perspective of cure is also reflected in the goal of treatment-free remission, with its surrogate markers, such as deep molecular response, also becoming the new endpoints of therapy efficacy in children and adolescents. Chronic myeloid leukemia was a fatal disease to children and adolescents in the past. Following the treatment paradigm of imatinib, it became a chronic disease with the potential of complete remission and even cure without the long-term hazards of allogeneic hematopoietic cell transplantation. The diagnosis and treatment of CML affect a child’s trajectory through life and important physiological events like development and procreation.

Sign in / Sign up

Export Citation Format

Share Document